|
|
Epsilon-3 Bio (E3Bio) is an early-stage biotech company established to exploit world-leading understanding of the pathways that clear damaged cells and proteins from tissues to maintain a healthy tissue architecture, from Cambridge University.
E3Bio has discovered a range of peptides and small molecules that stimulate autophagy (the clearance of intracellular damaged proteins) or phagocytosis (the clearance of extracellular debris). The lead compound, now in regulatory preclinical development, has impressive activity in non-clinical models of SLE. Other compounds may be useful in neurodegeneration, other chronic inflammatory diseases and dry age-related macular edema.
